A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™Senate Joint Resolution 82 (SJRES 82) from the 118th Congress is a joint resolution aimed at disapproving a rule submitted by the Food and Drug Administration (FDA) concerning medical devices, specifically laboratory developed tests (LDTs). The resolution seeks to use the congressional disapproval process under chapter 8 of title 5 of the United States Code to nullify the FDA's rule on this subject. The resolution was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions but ultimately failed or expired without further action. No detailed summary or full text of the bill is available in the source data.
SJRES 82 was a Senate resolution intended to reject an FDA rule on laboratory developed tests for medical devices but did not advance beyond committee referral and expired.
- The resolution targets an FDA rule related to medical devices and laboratory developed tests.
- It uses the congressional disapproval mechanism under chapter 8 of title 5, U.S. Code.
- The resolution was referred to the Senate Committee on Health, Education, Labor, and Pensions and did not progress further.
['Members of Congress seeking to exercise oversight over FDA regulations', 'Stakeholders in the medical device and laboratory testing sectors affected by FDA rules', 'Potentially patients and healthcare providers depending on the regulatory environment for laboratory developed tests']
['Lack of detailed bill text and official summary limits understanding of specific regulatory changes targeted', 'Use of the congressional disapproval process may raise questions about separation of powers and regulatory authority', 'Potential impacts on FDA’s regulatory oversight and enforcement capabilities for medical devices and laboratory tests']
The resolution was introduced in the Senate during the 118th Congress and referred to the Committee on Health, Education, Labor, and Pensions. It reflects congressional oversight activity related to FDA regulatory actions on medical devices, specifically laboratory developed tests. The resolution did not advance beyond committee referral and is recorded as failed or expired.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the resolution could set a precedent for congressional disapproval of future FDA or other agency rules, potentially influencing regulatory stability.', 'Stakeholders in the medical device and laboratory testing industries might experience uncertainty regarding regulatory requirements.', 'Potential shifts in FDA enforcement priorities or resource allocation if regulatory authority is curtailed.']
The absence of a detailed official summary and full bill text limits comprehensive analysis of the specific regulatory provisions targeted. Transparency would be improved by providing full text and detailed summaries to clarify the scope and implications of the disapproval resolution. Monitoring the use of congressional disapproval resolutions is important for understanding shifts in regulatory authority and oversight dynamics.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.